DDInter1917 DDInter1676
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Vandetanib {u} (Compound) resembles {v} (Compound) Erlotinib
Vandetanib {u} (Compound) treats {v} (Disease) thyroid cancer
Vandetanib {u} (Compound) binds {v} (Gene) FMO1
Vandetanib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Vandetanib {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Vandetanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Vandetanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Vandetanib {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Vandetanib (Compound) resembles Erlotinib (Compound)
Vandetanib (Compound) treats thyroid cancer (Disease)
Vandetanib (Compound) binds FMO1 (Gene)
Vandetanib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Vandetanib (Compound) causes Blood creatinine increased (Side Effect)
Vandetanib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Vandetanib may cause a minor interaction that can limit clinical effects when taken with Esomeprazole
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Vandetanib may lead to a major life threatening interaction when taken with Lefamulin